Lista de obras -

2-Aminobenzimidazoles as potent Aurora kinase inhibitors.

artículo científico publicado en 2009

4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase

artículo científico publicado en 2016

Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

artículo científico publicado en 2016

Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors

artículo científico publicado en 2008

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors

artículo científico publicado en 2008

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

artículo científico publicado en 2012

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2

artículo científico publicado en 2012

Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors ⬇️

artículo científico publicado el 24 de octubre de 2012

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor

artículo científico publicado en 2016

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

scientific article published on 04 April 2019

Discovery of a potent and selective aurora kinase inhibitor

artículo científico publicado en 2008

Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation

artículo científico publicado en 2014

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists

artículo científico publicado en 2010

Monomeric targeted protein degraders

artículo científico publicado en 2020

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

artículo científico publicado en 2015

Optimization of globomycin analogs as novel gram-negative antibiotics

artículo científico publicado en 2020

Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR.

artículo científico publicado en 2015

Structure of the essential inner membrane lipopolysaccharide-PbgA complex

scientific article published on 12 August 2020

Structure of theBrachydanio rerioPolo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme

artículo científico publicado en 2008

Structure–activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists ⬇️

artículo científico publicado el 5 de noviembre de 2010

Unstable Mechanisms of Resistance to Inhibitors of Escherichia coli Lipoprotein Signal Peptidase

artículo científico publicado en 2020

Lista de obras de

2-Aminobenzimidazoles as potent Aurora kinase inhibitors.

4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase

Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2

Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors ⬇️

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

Discovery of a potent and selective aurora kinase inhibitor

Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists

Monomeric targeted protein degraders

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

Optimization of globomycin analogs as novel gram-negative antibiotics

Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR.

Structure of the essential inner membrane lipopolysaccharide-PbgA complex

Structure of theBrachydanio rerioPolo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme

Structure–activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists ⬇️

Unstable Mechanisms of Resistance to Inhibitors of Escherichia coli Lipoprotein Signal Peptidase